A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles.

In this study, we demonstrate a simple strategy for enhanced immune response using a two-component dendritic cell (DC) targeted antigen delivery system. One component consists of a recombinant bifunctional fusion protein (bfFp) used for DC targeting, whereas, the other component is made of biotinylated PLGA nanoparticles that encapsulate the antigen. The fusion protein (bfFp) made of a truncated core-streptavidin fused to anti-DEC-205 single chain antibody (scFv) was mixed with ovalbumin-loaded biotinylated NPs that were formulated using biotin-PEG (2000)-PLGA, and the combination, bfFp functionalized NPs was used for DC targeted antigen delivery. In vitro DC uptake studies revealed a 2-fold higher receptor-mediated uptake of bfFp functionalized NPs when compared to non-targeted NPs. Immunization of the mice with the bfFp functionalized NPs in conjunction with DC maturation stimulus (anti-CD40 mAb) enhanced OVA-specific IgG and IgG subclass responses. Splenocytes of these mice secreted significantly higher levels of Th1 (IFN-γ and IL-2) cytokines upon ex vivo restimulation with OVA. The promising outcomes of the bfFp functionalized DC targeted system support its use as a versatile vaccine delivery system for the design of monovalent or polyvalent vaccines.

[1]  C. Lehr,et al.  Coupling of biotin-(poly(ethylene glycol))amine to poly(D,L-lactide-co-glycolide) nanoparticles for versatile surface modification. , 2007, Bioconjugate chemistry.

[2]  M. Rincón,et al.  The two faces of IL-6 on Th1/Th2 differentiation. , 2002, Molecular immunology.

[3]  Y. van Kooyk,et al.  'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells. , 2011, Current opinion in immunology.

[4]  J. Panyam,et al.  Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Steinman,et al.  Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC‐205/CD205‐positive mouse dendritic cells , 2008, European journal of immunology.

[6]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[7]  P. Wallace,et al.  Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells , 2007, Journal of Translational Medicine.

[8]  R. Steinman,et al.  The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal Compartments , 2000, The Journal of cell biology.

[9]  G. Schuler,et al.  Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. , 2010, Blood.

[10]  R. Steinman,et al.  Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. I. Expression on dendritic cells and other subsets of mouse leukocytes. , 1995, Cellular immunology.

[11]  A. Lavasanifar,et al.  Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. , 2011, Advanced drug delivery reviews.

[12]  R. Steinman,et al.  Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. , 2010, Blood.

[13]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[14]  Chandan Thomas,et al.  Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. , 2011, Molecular pharmaceutics.

[15]  Wenlei Jiang,et al.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. , 2005, Advanced drug delivery reviews.

[16]  Siddhartha Jain,et al.  The long-term potential of biodegradable poly(lactideco-glycolide) microparticles as the next-generation vaccine adjuvant , 2011, Expert review of vaccines.

[17]  A. Enk,et al.  Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. , 2007, Cellular immunology.

[18]  D. Irvine,et al.  Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium vivax Malaria Vaccine , 2012, PloS one.

[19]  G. Trinchieri,et al.  Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. , 1995, Journal of immunology.

[20]  Michel C. Nussenzweig,et al.  Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.

[21]  K. Shortman,et al.  Improving vaccines by targeting antigens to dendritic cells , 2009, Experimental & Molecular Medicine.

[22]  E. Cevher,et al.  Enhancement of immune response of HBsAg loaded poly (L-lactic acid) microspheres against Hepatitis B through incorporation of alum and chitosan , 2007, Journal of microencapsulation.

[23]  Shiladitya Sengupta,et al.  Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy , 2009, Proceedings of the National Academy of Sciences.

[24]  Changsheng Liu,et al.  In vitro macrophage uptake and in vivo biodistribution of long-circulation nanoparticles with poly(ethylene-glycol)-modified PLA (BAB type) triblock copolymer. , 2009, Colloids and surfaces. B, Biointerfaces.

[25]  Carl G. Figdor,et al.  Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting , 2007, Nature Reviews Immunology.

[26]  B. Gander,et al.  Development of synthetic biodegradable microparticulate vaccines: a roller coaster story , 2007, Expert review of vaccines.

[27]  Yvonne Perrie,et al.  Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Praveen Elamanchili,et al.  Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. , 2004, Vaccine.

[29]  L. Vitale,et al.  Antigenic Targeting of the Human Mannose Receptor Induces Tumor Immunity1 , 2007, The Journal of Immunology.

[30]  A. Salem,et al.  Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma , 2009, Cancer Immunology, Immunotherapy.

[31]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[32]  C. Figdor,et al.  Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. , 2011, Blood.

[33]  Michel C. Nussenzweig,et al.  Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.

[34]  C. Demangel,et al.  Stimulation of Dendritic Cells via CD40 Enhances Immune Responses to Mycobacterium tuberculosisInfection , 2001, Infection and Immunity.

[35]  R. Steinman,et al.  Cutting Edge: Langerin/CD207 Receptor on Dendritic Cells Mediates Efficient Antigen Presentation on MHC I and II Products In Vivo1 , 2008, The Journal of Immunology.

[36]  L. Bockenstedt,et al.  The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. , 2011, Biomaterials.

[37]  M. Wright,et al.  The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. , 2008, Blood.

[38]  Sherief Essa,et al.  Characterization of rhodamine loaded PEG-g-PLA nanoparticles (NPs): effect of poly(ethylene glycol) grafting density. , 2011, International journal of pharmaceutics.

[39]  Fernando Albericio,et al.  Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[40]  R. Steinman,et al.  Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses , 2006, The Journal of experimental medicine.

[41]  K. Kaur,et al.  Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein. , 2012, Molecular pharmaceutics.

[42]  Scott N. Mueller,et al.  Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype , 2011, The Journal of Immunology.

[43]  M. Suresh,et al.  A versatile bifunctional dendritic cell targeting vaccine vector. , 2009, Molecular pharmaceutics.

[44]  D. Irvine,et al.  Particulate vaccines: on the quest for optimal delivery and immune response. , 2011, Drug discovery today.

[45]  R. Steinman,et al.  Dendritic cell‐targeted protein vaccines: a novel approach to induce T‐cell immunity , 2012, Journal of internal medicine.

[46]  A. Enk,et al.  Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule , 2008, Clinical Cancer Research.

[47]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[48]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[49]  C. Figdor,et al.  Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. , 2005, Blood.

[50]  C. Figdor,et al.  The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. , 2011, Biomaterials.

[51]  D. Keskin,et al.  Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. , 2011, Biomaterials.

[52]  C. Figdor,et al.  In Vivo Targeting of DC-SIGN-positive Antigen-presenting Cells in a Nonhuman Primate Model , 2007, Journal of immunotherapy.

[53]  M. Carrington,et al.  DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes , 2007, Proceedings of the National Academy of Sciences.